Please Scroll Down to See Forums Below 
MrMakaveli
New member
Bromocriptine reduces obesity, glucose intolerance and extracellular monoamine
metabolite levels in the ventromedial hypothalamus of Syrian hamsters.
Luo S, Meier AH, Cincotta AH
Ergo Science Corporation, Charlestown, Mass 02129, USA. [email protected]
We examined whether reductions in body fat stores and insulin resistance in
Syrian hamsters induced by bromocriptine are associated with reductions in
daily norepinephrine (NE) and serotonin activities as indicated by their
extracellular metabolite levels in the ventromedial hypothalamus (VMH). High
levels of these monoamines within the VMH have been suspected to induce obesity
and insulin resistance. Microdialysate samples from the VMH of freely moving
obese male hamsters (BW: 208 +/- 5 g) were collected hourly over a 25-hour
period before bromocriptine treatment, during the first day of and after 2
weeks of bromocriptine treatment (800 microg/animal daily, i.p.), and body
composition and glucose tolerance analyses were conducted before and after 2
weeks of treatments. The microdialysate samples were analyzed by HPLC for
metabolites of serotonin: 5-hydroxy-indoleacetic acid (5-HIAA), NE:
3-methoxy-4-hydroxy-phenylglycol (MHPG), and dopamine: homovanillic acid (HVA).
Bromocriptine treatment for 14 days significantly reduced body fat by 60% and
areas under the glucose and insulin curves during a glucose tolerance test by
50 and 46%, respectively. Concurrently, extracellular VMH contents of 5-HIAA,
MHPG, and HVA were reduced by 50, 29 and 66%, respectively (p < 0.05).
Similarly, VMH 5-HIAA and MHPG contents were 48 and 44% less, respectively (p <
0.05), in naturally glucose-tolerant hamsters compared with naturally
glucose-intolerant hamsters. Bromocriptine induced reductions of body fat, and
improvements in glucose intolerance may result in part from its ability to
decrease serotonin and NE activities in the VMH.
PMID: 9695933, UI: 98359104
Diabetes Care 1997 Nov;20(11):1697-701
Ok so...
Would ephedrine (or Theopylline found in T-Rex) negate this effect of Bromo by raising norepinephrine or serotonin activities in the ventromedial hypothalamus?
(John Williams on MWF said this)
Brain after reading study =
metabolite levels in the ventromedial hypothalamus of Syrian hamsters.
Luo S, Meier AH, Cincotta AH
Ergo Science Corporation, Charlestown, Mass 02129, USA. [email protected]
We examined whether reductions in body fat stores and insulin resistance in
Syrian hamsters induced by bromocriptine are associated with reductions in
daily norepinephrine (NE) and serotonin activities as indicated by their
extracellular metabolite levels in the ventromedial hypothalamus (VMH). High
levels of these monoamines within the VMH have been suspected to induce obesity
and insulin resistance. Microdialysate samples from the VMH of freely moving
obese male hamsters (BW: 208 +/- 5 g) were collected hourly over a 25-hour
period before bromocriptine treatment, during the first day of and after 2
weeks of bromocriptine treatment (800 microg/animal daily, i.p.), and body
composition and glucose tolerance analyses were conducted before and after 2
weeks of treatments. The microdialysate samples were analyzed by HPLC for
metabolites of serotonin: 5-hydroxy-indoleacetic acid (5-HIAA), NE:
3-methoxy-4-hydroxy-phenylglycol (MHPG), and dopamine: homovanillic acid (HVA).
Bromocriptine treatment for 14 days significantly reduced body fat by 60% and
areas under the glucose and insulin curves during a glucose tolerance test by
50 and 46%, respectively. Concurrently, extracellular VMH contents of 5-HIAA,
MHPG, and HVA were reduced by 50, 29 and 66%, respectively (p < 0.05).
Similarly, VMH 5-HIAA and MHPG contents were 48 and 44% less, respectively (p <
0.05), in naturally glucose-tolerant hamsters compared with naturally
glucose-intolerant hamsters. Bromocriptine induced reductions of body fat, and
improvements in glucose intolerance may result in part from its ability to
decrease serotonin and NE activities in the VMH.
PMID: 9695933, UI: 98359104
Diabetes Care 1997 Nov;20(11):1697-701
Ok so...
Would ephedrine (or Theopylline found in T-Rex) negate this effect of Bromo by raising norepinephrine or serotonin activities in the ventromedial hypothalamus?
(John Williams on MWF said this)
Brain after reading study =
